Market Research Logo

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Summary


Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. The following report covers all immunology disorders, with a particular focus on four key areas: rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD) and transplant rejection/graft versus host disease (GVHD).

Immunology drugs market is projected to grow to $113 billion in 2023, at a compound annual growth rate (CAGR) of over 8%. The market size in the US is expected to increase at a CAGR of 6.58%, therefore accounting for approximately half of the global immunology market.

The prevalence populations of many indications within immunology are increasing, which is one of the major drivers of the expected market growth. For example, the prevalence population of RA across the seven major markets is expected to increase from 6.11 million in 2016 to 6.66 million in 2023.

Immunology market contains a number of blockbuster drugs, most of which are mAbs that target tumor necrosis alpha (TNF-α), a key pro-inflammatory cytokine. These include Humira (adalimumab), the most successful drug industry-wide, as well as Remicade (infliximab), Rituxan (rituximab), Simponi (golimumab) and Cimzia (certolizumab pegol). However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced dominance.

The first TNF biosimilars were approved several years ago when the first patents expired, but they are only now starting to have an impact on the revenue of their premium counterparts. For example, Remsima and Inflectra are Remicade biosimilars that have been approved in the EU, and Inflectra also has FDA approval to be marketed in 2018 when the patent for Remicade expires in the US. These biosimilars are exerting a very noticeable impact on Remicade’s revenue, which peaked in 2014 at $9.9 billion but is expected to fall to $3 billion by 2023.

Furthermore, there are also several drugs that have recently been approved - such as Cosentyx and Otezla - and several in late-stage pipeline development - such as, filgotinib, AR-101 and upadacitinib tartrate - that are expected to become blockbuster drugs over the forecast period, generating further market growth within immunology.

The report Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs provides the following -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
  • Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.
Scope
  • The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.
  • Overall, there are 2,070 immunology products in the pipeline.
  • Which molecular targets are most prominent within the pipeline?
  • How do the key indications differ in terms of molecule type?
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?
  • The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.
  • Which products will contribute to market growth most, and which will achieve blockbuster status?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
  • What CAGR will these companies register in the forecast period?
  • How many strategic consolidations have been completed in the past decade?
  • Which types of assets attract the largest deal values?
Reasons to buy
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
  • Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.


  • Executive Summary
  • Introduction
    • Therapy Area Overview
      • Rheumatoid Arthritis
      • Psoriasis
      • Inflammatory Bowel Disease
      • Graft Versus Host Disease and Transplant Rejection
    • Symptoms
      • Table Immunology Drugs Market, Global, Symptoms of RA, Psoriasis and IBD, 2018
      • Table Immunology Drugs Market, Global, Organ-Specific Symptoms of Transplant Rejection, 2018
      • Table Immunology Drugs Market, Global, Organ-Specific Symptoms of Acute GVHD, 2018
      • Table Immunology Drugs Market, Global, Organ-Specific Symptoms of Chronic GVHD, 2018
    • Diagnosis
      • Rheumatoid Arthritis
      • Psoriasis
      • Inflammatory Bowel Disease
      • Graft Versus Host Disease and Transplant Rejection
    • Etiology and Pathophysiology
      • Table Immunology Drugs Market, Etiology of RA, Psoriasis, IBD and GVHD, 2018
      • Rheumatoid Arthritis
      • Psoriasis
      • Inflammatory Bowel Disease
      • Graft Versus Host Disease and Transplant Rejection
    • Epidemiology
      • Table Immunology Drugs Market, 7MM, Epidemiology of Key Immunology Indications, 2018
      • Rheumatoid Arthritis
        • Table Figure 1: Immunology Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2016– 2023
      • Psoriasis
        • Table Figure 2: Immunology Drugs Market, 7MM, Epidemiology Patterns for Psoriasis, 2016–2023
      • Inflammatory Bowel Disease
        • Table Figure 3: Immunology Drugs Market, 7MM, Epidemiology Patterns for Crohn's Disease, 2016–2023
        • Table Figure 4: Immunology Drugs Market, Epidemiology Patterns for Ulcerative colitis, 2016–2023
      • Graft Versus Host Disease and Transplant Rejection
        • Table Figure 5: Immunology Drugs Market, Epidemiology Patterns for Graft Versus Host Disease, 2016– 2023
    • Co-morbidities and Complications
    • Treatment
      • Rheumatoid Arthritis
      • Psoriasis
      • Inflammatory Bowel Disease
      • Graft-Versus-Host Disease and Transplant Rejection
  • Key Marketed Products
    • Overview
      • Table Figure 6: Immunology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
    • Humira (adalimumab) –AbbVie
      • Table Immunology Drugs Market, Global, Approved Indications for Humira, 2018
      • Table Figure 7: Immunology Drugs Market, Global, Annual Revenues for Humira ($bn), 2006–2023
    • Enbrel (etanercept) - Amgen
      • Table Immunology Drugs Market, Global, Approved Indications for Enbrel, 2018
      • Table Figure 8: Immunology Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006–2023
    • Remicade (infliximab) –Johnson & Johnson
      • Table Immunology Drugs Market, Global, Approved Indications for Remicade, 2018
      • Table Figure 9: Immunology Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006–2023
    • Rituxan (rituximab) –Roche
      • Table Immunology Drugs Market, Global, Approved Indications for Rituxan, 2018
      • Table Figure 10: Immunology Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006–2023
    • Stelara (ustekinumab) –Johnson & Johnson
      • Table Immunology Drugs Market, Global, Approved Indications for Stelara, 2018
      • Table Figure 11: Immunology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010–2023
    • Simponi (golimumab) –Johnson & Johnson
      • Table Immunology Drugs Market, Global, Approved Indications for Simponi, 2018
      • Table Figure 12: Immunology Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010–2023
    • Orencia (abatacept) –Bristol-Myers Squibb
      • Table Immunology Drugs Market, Global, Approved Indications for Orencia, 2018
      • Table Figure 13: Immunology Drugs Market, Global, Annual Revenue for Orencia ($bn), 2006–2023
    • Tysabri (natalizumab) –Biogen
      • Table Immunology Drugs Market, Global, Approved Indications for Tysabri, 2018
      • Table Figure 14: Immunology Drugs Market, Global, Annual Revenue for Tysabri ($bn), 2006–2023
    • Actemra (tocilizumab) –Roche
      • Table Immunology Drugs Market, Global, Approved Indications for Actemra, 2018
      • Table Figure 15: Immunology Drugs Market, Global, Annual Revenues for Actemra ($bn), 2006–2023
    • Prograf (tacrolimus) –Astellas
      • Table Immunology Drugs Market, Global, Approved Indications for Prograf, 2018
      • Table Figure 16: Immunology Drugs Market, Global, Annual Revenue for Prograf ($bn), 2006–2023
    • Cimzia (certolizumab) –UCB
      • Table Immunology Drugs Market, Global, Approved Indications for Cimzia, 2018
      • Table Figure 17: Immunology Drugs Market, Global, Annual Revenue for Cimzia ($bn), 2008–2023
    • Entyvio (vedolizumab) - Takeda
      • Table Immunology Drugs Market, Global, Approved Indications for Entyvio, 2018
      • Table Figure 18: Immunology Drugs Market, Global, Annual Revenue for Entyvio ($bn), 2014–2023
    • Cosentyx (secukinumab) - Novartis
      • Table Immunology Drugs Market, Global, Approved Indications for Cosentyx, 2018
      • Table Figure 19: Immunology Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015–2023
    • Otezla (apremilast) - Celgene
      • Table Immunology Drugs Market, Global, Approved Indications for Otezla, 2018
      • Table Figure 20: Immunology Drugs Market, Global, Annual Revenue for Otezla($bn), 2014–2023
    • Xeljanz (tofacitinib) –Pfizer
      • Table Immunology Drugs Market, Global, Approved Indications for Xeljanz, 2018
      • Table Figure 21: Immunology Drugs Market, Global, Annual Revenues for Xeljanz ($bn), 2012–2023
    • Taltz (ixekizumab) –Eli Lilly
      • Table Immunology Drugs Market, Global, Approved Indications for Taltz, 2018
      • Table Figure 22: Immunology Drugs Market, Global, Annual Revenue for Taltz ($bn), 2016–2023
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 23: Immunology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
    • Pipeline Development Landscape
      • Table Figure 24: Immunology Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2018
      • Table Figure 25: Immunology Drugs Market, Global, Pipeline by Program Type, 2018
      • Table Figure 26: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2018
      • Table Figure 27: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2018
    • Molecular Targets in the Pipeline
      • Table Figure 28: Immunology Drugs Market, Pipeline by Molecular Target, 2018
      • Table Figure 29: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2018
    • Clinical Trials Landscape
      • Clinical Trial Failure Rates
        • Table Figure 30: Immunology Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006–2018
        • Table Figure 31: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006–2017
        • Table Figure 32: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006–2017
        • Table Figure 33: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006–2017
      • Clinical Trial Duration
        • Table Figure 34: Immunology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017
        • Table Figure 35: Immunology Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006–2017
        • Table Figure 36: Immunology Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2017
        • Table Figure 37: Immunology Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006–2017
      • Clinical Trial Size
        • Table Figure 38: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2017
        • Table Figure 39: Immunology Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006–2017
        • Table Figure 40: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2017
        • Table Figure 41: Immunology Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006–2017
      • Cumulative Clinical Program Size
        • Table Figure 42: Immunology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2017
        • Table Figure 43: Immunology Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006–2017
        • Table Figure 44: Immunology Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2017
        • Table Figure 45: Immunology Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006–2017
    • Assessment of Key Late-Stage Pipeline Products
      • Filgotinib – Galapagos and Gilead Sciences
        • Table Figure 46: Immunology Drugs Market, Global, Annual Revenue Forecast for Filgotinib ($m), 2019–2023
      • AR-101 – Aimmune Therapeutics
        • Table Figure 47: Immunology Drugs Market, Global, Annual Revenue Forecast for AR-101 ($m), 2019–2023
      • Upadacitinib tartrate – AbbVie
        • Table Figure 48: Immunology Drugs Market, Global, Annual Revenue Forecast for Upadacitinib ($m), 2019– 2023
      • Lanadelumab – Shire
        • Table Figure 49: Immunology, Global, Annual Revenue Forecast for Lanadelumab ($m), 2018–2023
      • Ozanimod hydrochloride – Celgene
        • Table Figure 50: Immunology Drugs Market, Global, Annual Revenue Forecast for Ozanimod ($m), 2018– 2023
      • Risankizumab – AbbVie
        • Table Figure 51: Immunology Drugs Market, Global, Annual Revenue Forecast for Risankizumab ($m), 2018–2023
    • Conclusion
  • Multi-scenario Market Forecast to 2023
    • Overall Market Size
      • Table Figure 52: Immunology Drugs Market, Global, Market Size ($bn), 2016–2023
      • Table Immunology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023
    • Generic Penetration
      • Table Figure 53: Immunology Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016–2023
      • Table Immunology Drugs Market, Global, Usage of Generics Across Key Indications, 2018
    • Revenue Forecast by Molecular Target
      • Cytokines and Cytokine Receptors
        • Table Figure 54: Immunology Drugs Market, Global, Annual Revenue Forecast for Cytokines and Cytokine Receptors ($bn), 2016–2023
      • Intracellular Signal Transducers
        • Table Figure 55: Immunology Drugs Market, Global, Annual Revenue Forecast for Intracellular Signal Transducers ($bn), 2016–2023
      • Cell Surface Antigens
        • Table Figure 56: Immunology Drugs Market, Global, Annual Revenue Forecast for Cell Surface Antigens ($bn), 2016–2023
      • Intercellular Interaction and Adhesion Molecules
        • Table Figure 57: Immunology Drugs Market, Global, Annual Revenue Forecast for Intercellular Interaction and Adhesion Molecules ($bn), 2016–2023
  • Company Analysis and Positioning
    • Table Figure 58: Immunology Drugs Market, Global, Company Analysis Matrix, 2016–2023
    • Table Figure 59: Immunology Drugs Market, Global, Cluster by Growth and Market Share, 2016–2023
    • Revenue and Market Share Analysis by Company
      • Table Immunology Drugs Market, Global, Forecast Revenue by Company (%), 2016–2023
      • Table Figure 60: Immunology Drugs Market, Global, Forecast Market Share by Company (%), 2016–2023
      • Table Figure 61: Immunology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016–2023
      • Table Figure 62: Immunology Drugs Market, Global, Revenues by Route of Acquisition, 2016–2023
      • AbbVie
        • Table Figure 63: Immunology Drugs Market, Global, AbbVie, Annual Revenue Forecast ($bn), 2016–2023
      • Johnson & Johnson
        • Table Figure 64: Immunology Drugs Market, Global, Johnson & Johnson, Annual Revenue Forecast ($bn), 2016–2023
      • Novartis
        • Table Figure 65: Immunology Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2016–2023
      • Pfizer
        • Table Figure 66: Immunology Drugs Market, Global, Pfizer, Annual Revenue Forecast ($bn), 2016–2023
      • Roche
        • Table Figure 67: Immunology Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2016–2023
      • Amgen
        • Table Figure 68: Immunology Drugs Market, Global, Amgen, Annual Revenue Forecast ($bn), 2016–2023
      • Celgene
        • Table Figure 69: Immunology Drugs Market, Global, Celgene, Annual Revenue Forecast ($bn), 2016–2023
      • Eli Lilly
        • Table Figure 70: Immunology Drugs Market, Global, Eli Lilly, Annual Revenue Forecast ($bn), 2016–2023
    • Company Landscape
      • Table Figure 71: Immunology Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 72: Immunology Drugs Market, Global, Pipeline, High-Activity and Late-Stage Pipeline Developers by Level of Specialization, 2018
      • Table Figure 73: Immunology Drugs Market, Global, Proportion of Total Company Revenue Attributed to Immunology Disorders, 2016–2023
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Year and Value
        • Table Figure 74: Immunology Drugs Market, Global, Licensing Deals by Region, Year and Value, 2006–2018
      • Deals by Indication
        • Table Figure 75: Immunology Drugs Market, Global, Licensing Deals by Key Indication, 2006–2018
      • Deals by Stage of Development
        • Table Figure 76: Immunology Market, Global, Licensing Deals by Stage of Development, 2006–2018
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 77: Immunology Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018
      • Table for Licensing Deals with Disclosed Values
        • Table Figure 78: Immunology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018
    • Co-development Deals
      • Deals by Region, Year and Value
        • Table Figure 82: Immunology Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018
      • Deals by Indication
        • Table Figure 83: Immunology Drugs Market, Global, Co-development Deals by Key Indication, 2006–2018
      • Deals by Stage of Development
        • Table Figure 84: Immunology Drugs Market, Global, Co-development Deals by Stage of Development, 2006–2018
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 85: Immunology Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018
      • Table for Co-development Deals with Disclosed Values
        • Table Figure 86: Immunology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006– 2018
  • Appendix
    • References
    • Figures of All Clinical Stage Pipeline Products
      • Table Figure 88: Immunology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018
    • Abbreviations
    • Disease List
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report